Pharma Demand Intelligence
Lot-level expiry, cold-chain breaks, and overstock risk—powered insights.
TAB-SAB Pharma
Demand Overview | Mar 2025
Last Updated: Mar 10, 2025
Show Insights
Forecast Accuracy
Target: 95%
91.2%
↑ 3.4%
Below target
Forecast Bias
Target: 5%
8.8%
↓ 3.4%
Below target
Sales Quantity
Target: 4700000
4326K
↓ 788000
Below target
Margin Impact
-0.42pts
↓ 0.18pts
Neg target
Forecast vs. Sales Order | Quantity
Key Insight:
Forecast accuracy has degraded significantly in Q3-Q4 2025, with actual sales averaging 65% below forecast. ML model predicts this trend will stabilize in Q1 2026 due to seasonal factors and adjusted customer forecasts.
Forecast Bias | Customer
Top 3 customers (Ash, Birch, Juniper) consistently overforecast by 23-27%, accounting for 56% of total forecast variance.
Forecast vs Sales | Product
Supplements show mixed performance: Glucosamine exceeds forecast by 11.8% while Vitamin C (-2.4%) and Calcium (-1.6%) underperform. Doxycycline shows largest negative variance (-6.1%).
Financial Impact Analysis
Revenue at Risk
$3.4M
Margin at Risk
$684K
Investment Needed
$920K
Expected ROI
2.8x
Payback Period
15 months